The United States Food and Drug Administration (FDA) has approved a drug called Palforzia which mitigates allergic reactions to peanuts. This treatment will be offered to individuals ages 4 through 17 years with a confirmed peanut allergy diagnosis.
Even while taking Palforzia, those who are allergic must continue to avoid peanuts in their diets at all times. It has been reported that the treatment consists of three phases: Initial Dose Escalation, Up-Dosing, and Maintenance.
According to a press statement, “The effectiveness of Palforzia is supported by a randomized, double-blind, placebo-controlled study conducted in the U.S., Canada and Europe in approximately 500 peanut-allergic individuals.”
The results showed 67.2% of the Palforzia recipients were able to tolerate a 600 mg peanut protein dose. The FDA asks that the drug only be administered to patients in a setting equipped to monitor the patient and able to manage the possible anaphylaxis outcome.
Although the FDA has granted approval, it will only be available through specially certified pharmacies and healthcare providers. Patients must be aware of the fact that the need for continued dietary peanut avoidance is crucial.